Program Focus Discovery Preclinical Clinical

CPI-003 ▼

 Therapeutic alpha for underserved metastatic cancer
Targeting IND in 2026
Additional Details:

CPI-003 is Curadel’s lead zwitterionic targeted alpha therapy. It is focused initially in metastatic cancer, which has high unmet needs. Multiple targeting ligands are added to its zwitterionic backbone to bind to tumors quickly after intravenous injection, avoid normal tissues and organs, and clear rapidly from the body via renal filtration and elimination into urine. Rapid and specific binding, clearance, and cell kill creates a huge therapeutic window and heralds improvement of TAT therapy that is generations ahead of current and emerging market options.

ZW800-1 ▼

 First in class zwitterionic ureter imaging drugs
Pivotal trial (exclusive distribution agreement)
Additional Details:

  • Curadel’s first zwitterionic imaging drug ZW800-1, also known as nizaracianine triflutate, was the world’s first zwitterionic NIR fluorophore. It is used by surgeons to identify and avoid the ureters in real-time during abdominopelvic surgery to avoid damage, which often results in significant morbidity and occasionally mortality. ZW800-1 is the subject of an exclusive distribution agreement with a Tier 1 medical device company and is currently undergoing its pivotal trial.
  • Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery (TRIPHASE)(NCT06101745)

CPI-005 ▼

 Next-generation MRI contrast agent
POC underway (out-licensing)
Additional Details:

Novel zwitterionic chelator for MRI with best-in-class relaxivity and minimal retention.

Responsive Table with Full-Width Progress Bar Table

CPI-003

CPI-003

Focus: Therapeutic alpha for underserved metastatic cancer

Discovery Pre-Clinical Clinical
Targeting IND in 2026

Details: CPI-003 is Curadel’s lead zwitterionic targeted alpha therapy. It is focused initially in metastatic cancer, which has high unmet needs. Multiple targeting ligands are added to its zwitterionic backbone to bind to tumors quickly after intravenous injection, avoid normal tissues and organs, and clear rapidly from the body via renal filtration and elimination into urine. Rapid and specific binding, clearance, and cell kill creates a huge therapeutic window and heralds improvement of TAT therapy that is generations ahead of current and emerging market options.

ZW800-1

ZW800-1

Focus: First-in-class zwitterionic ureter imaging drugs

Discovery Pre-Clinical Clinical
Pivotal trial in progress

Details:

  • Curadel’s first zwitterionic imaging drug ZW800-1, also known as nizaracianine triflutate, was the world’s first zwitterionic NIR fluorophore. It is used by surgeons to identify and avoid the ureters in real-time during abdominopelvic surgery to avoid damage, which often results in significant morbidity and occasionally mortality. ZW800-1 is the subject of an exclusive distribution agreement with a Tier 1 medical device company and is currently undergoing its pivotal trial.
  • Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery (TRIPHASE)( NCT06101745)

CPI-005

CPI-005

Focus: Next-generation MRI contrast agent

Discovery Pre-Clinical Clinical
POC underway

Details: Novel zwitterionic chelator for MRI with best-in-class relaxivity and minimal retention.

Publications

FDA Expanded Access Policy

View Policy